Posted by Michael Wonder on 20 Dec 2018
Institute for Clinical and Economic Review provides policy recommendations for biologic treatments for uncontrolled asthma
20 December 2018 - Expert roundtable suggests that lower prices, needed to align pricing fairly with the added value for patients, could result in broader patient access.
The ICER today released a Final Evidence Report and Report-at-a-Glance assessing the comparative clinical effectiveness and value of biologic treatments for asthma associated with type 2 inflammation and/or allergic asthma. The report focuses on dupilumab (Dupixent, Sanofi/Regeneron), omalizumab (Xolair, Genentech/Novartis), mepolizumab (Nucala, GlaxoSmithKline), reslizumab (Cinqair, Teva), and benralizumab (Fasenra, AstraZeneca). ICER previously reviewed mepolizumab for its use in severe eosinophilic asthma and dupilumab for its use in atopic dermatitis.
ICER’s report was reviewed at the November 2018 public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), one of ICER’s three independent evidence appraisal committees. During the meeting, the panel found that the evidence demonstrated dupilumab to be clinically superior to the standard of care, but that the evidence was insufficient to distinguish between dupilumab and the other biologics approved for asthma with an eosinophilic phenotype.
